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Abstract
Novel N-α-haloacylated homoserine lactones, in which a halogen atom was introduced at the α-position of the carbonyl function of
the N-acyl chain, have been studied as quorum sensing (QS) modulators and compared with a library of natural N-acylated
homoserine lactones (AHLs). The series of novel analogues consists of α-chloro, α-bromo and α-iodo AHL analogues. Further-
more, the biological QS activity of the synthetic AHL analogues compared to the natural AHLs was evaluated. Halogenated
analogues demonstrated a reduced activity in the Escherichia coli JB523 bioassay, with the α-iodo lactones being the less active
ones and the α-chloro AHLs the most potent QS agonists. Most of the α-haloacylated analogues did not exhibit a significant reduc-
tion when tested in the QS inhibition test. Therefore, these novel analogues could be utilized as chemical probes for QS
structure–activity studies.
Introduction
Quorum sensing (QS) is the communication system used by
bacteria allowing them to adapt to their environment [1].
Bacteria relying on QS secrete signal molecules, called autoin-
ducers, in order to control the expression of specific target
genes important for phenotype expression (e.g., biofilm forma-
tion, bioluminescence, virulence expression, etc.) in a popula-
tion density dependent manner [2]. The importance of QS for
virulence development in pathogenic bacteria nowadays is
obvious [3]. Therefore, quorum sensing modulation is seen as a
new anti-infective strategy [4]. Although the described QS
systems can regulate virulence, it is believed that they do not
affect the viability of bacteria and it could be expected that
disruption of QS will not likely create a selective pressure
towards resistant organisms [5]. Despite recent reports
supporting this theory, it has to be noted that this view point has
been challenged and is still under debate among scientists [6,7].
Most Gram-negative bacteria use N-acylated homoserine
lactones (AHLs) as signal molecules [8]. The general structure
of these compounds consist of a lactone ring with an acyl side
chain [9]. The length of the acyl chain is usually between
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4–18 carbons and the functionality at the β-carbon position can
vary. The QS mechanism in these bacteria relies generally upon
two components: a LuxI like protein which is a synthase that
produces the autoinducer and a transcriptional activator, i.e, a
LuxR like protein which binds to the autoinducer [10]. Different
bacterial strains were shown to respond to and produce different
but specific autoinducers [11]. Furthermore, recent studies
reveal that AHLs facilitate both intra-species communication
and inter-kingdom interactions [12].
The strong impact of AHLs on bacterial behaviour has gained
the attention of scientists towards designing AHL mimics that
can modulate QS [13,14]. However, the high specificity and
affinity that most of the receptors show towards their natural
ligands does not allow the design of analogues with high struc-
tural deviation from the parent autoinducer [15]. In biological
processes, covalent binding and non-covalent interactions are
encountered in many protein-ligand interactions as well as in
protein secondary structures and are of great significance. In the
past years, it was shown that the proximity of carbonyl groups
can influence the conformation of molecules by an n→π* inter-
action [16,17]. Newberry and Raines, very recently proposed
that tailored small molecules, that could attenuate this n→π*
interaction, in which the lone pair (n) of the N-acyl oxygen
overlays with the π* orbital of the lactone carbonyl group, could
increase the affinity of AHLs to their cognate receptors [18]. It
was shown that introduction of halogens as electron-with-
drawing groups in the N-acyl chain reduced the nucleophilicity
of the donor oxygen and led to attenuation of the n→π* inter-
action (Figure 1). Moreover, inhibition of bacterial QS was
recently demonstrated by a set of electrophilic probes (which
included halogenated analogues of AHLs) that could covalently
bind in the LasR binding pocket of Pseudomonas aeruginosa
[15]. Therefore, designing analogues with small reactive
moieties, such as halogenated carbon atoms, that could be
involved in such interactions seem an interesting strategy to be
explored.
Figure 1: Structure of N-acyl homoserine lactone (AHL) and putative
n→π* interaction. Attenuation of n→π* interaction in N-tribromoacetyl
homoserine lactone (TBAHL) as suggested by Newberry and Raines
[18]. General structure of compounds used in this study (α-halo-AHL).
Surprisingly, most of the studies focus on altering the fatty acid
tail or the lactone ring of the AHL molecules [14,19], while
modifications at the α-carbon position with respect to the car-
bonyl function of the N-acyl chain are scarce up to date. It was
envisioned that modification of an AHL molecule by introduc-
tion of a halogen atom in α-position of the carbonyl group of
the N-acyl chain could possibly generate a novel class of QS
modulators. Halogenated fatty acids have been reported as
minor components of microorganisms, algae, marine inverte-
brates, and some plants and animals [20,21]. Interest in these
naturally occurring products is high as they often exhibit fasci-
nating biological activities [22-24]. Furthermore, due to the re-
activity of halogen substituents, this novel class of compounds
can be regarded as building blocks for further elaborations
towards new analogues of AHLs. Therefore this study aimed
towards the synthesis and biological evaluation of a series of
novel halogenated analogues, in which a chlorine, bromine or
iodine atom was introduced. To further evaluate the influence of
a halogen introduction, the bioactivity of these novel N-α-haloa-
cylated homoserine lactones was directly compared with a
broad library of naturally occurring AHLs.
Results and Discussion
Synthesis of N-acylated homoserine lactones
and halogenated analogues
(S)-Homoserine lactone hydrobromide (1) was prepared as
previously described by reaction of (S)-methionine with
bromoacetic acid [25]. Reaction of homoserine lactone hydro-
bromide (1) with the corresponding acid chloride 2 under
Schotten–Baumann conditions gave the desired N-acylated
homoserine lactones 3a–f (Scheme 1) [26]. These reaction
conditions were used for the preparation of AHLs with unfunc-
tionalized acyl chains in a convenient way. The brominated
fatty acids 5, except the commercially available α-bromohexa-
noic acid (5a), were prepared by a Hell–Volhard–Zelinsky bro-
mination of the corresponding fatty acid 4 with molecular
bromine and thionyl chloride [27]. These reaction conditions
allowed the synthesis of α-brominated fatty acids 5 in a highly
selective and efficient manner.
Brominated AHL analogues 6a–f (dr 1:1) were prepared in
acceptable yields by 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide (EDC)-mediated coupling of the appropriate α-bromo
fatty acid 5 with (S)-homoserine lactone 1 (Scheme 2).
For α-iodo fatty acids 7, two different routes were evaluated.
Iodinated fatty acids 7e,f were prepared via reaction of the
corresponding fatty acids 4e,f with iodine and chlorosulfonic
acid [28]. However, this transformation was not quantitative as
it resulted in a mixture of both iodinated and non-iodinated fatty
acids. Therefore, α-iodo fatty acids 7a–d were prepared via
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Scheme 1: Synthesis of natural AHLs 3a–f.
Scheme 2: Synthesis of brominated AHLs 6a-f and iodinated AHLs 8a–f (#commercially available compound).
direct substitution of the corresponding α-bromo fatty acids
5a–d with sodium iodide in 2-butanone [27]. The iodinated
AHL analogues 8a–f (dr 1:1) were subsequently prepared under
the same coupling conditions as for the brominated analogues 6
(Scheme 2). For compounds 8e,f, the above mentioned mixtures
of α-iodo fatty acids 7e,f and fatty acids 4e,f were used and the
desired α-iodinated lactones 8e,f could successfully be
separated from the reaction mixture via column chromatog-
raphy.
Chlorinated AHL analogues 11a–f were prepared via a one pot
procedure (Scheme 3). In this route the acylphosphonates 9a–f
were prepared by an Arbuzov reaction and were subsequently
chlorinated via reaction with sulfuryl chloride [29,30].
The phosphonate function is used as a strong activating group
for the enolization of the carbonyl function facilitating α-mono-
chlorination under mild conditions. α-Chlorinated acylphospho-
nates can be easily cleaved by a nucleophile with the expulsion
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Scheme 3: Synthesis of chlorinated AHL analogues 11a–f.
of phosphite. Therefore, the α-chloro acylphosphonates 10a–f
were transformed to the corresponding chlorinated AHL
analogues 11a–f via reaction with S-homoserine lactone hydro-
bromide (1) and triethylamine (Scheme 3).
Biological evaluation
The above mentioned natural AHLs 3 and their halogenated
analogues 6, 8 and 11 were first tested for their ability to in-
duce fluorescence in the Escherichia coli JB523 biosensor
(Table 1). Escherichia coli JB523 is a highly sensitive reporter
strain that contains plasmid pJBA130 derived from the LuxR-
PluxI quorum sensing operon of Vibrio fischeri expressing the
production of stable green fluorescent protein (GFP) in response
to exogenous AHLs [31]. In addition, the ability of this
biosensor to respond to a broad range of chain lengths and
functionalization makes it a good choice for the study of struc-
ture–activity relationships of synthesized analogues.
The ability of the natural AHLs 3 and their halogenated
analogues 6, 8 and 11 to induce fluorescence was expressed as
percentage of relative fluorescence. The activity of these com-
pounds was compared with fluorescence induced by 50 nM of
N-3-oxohexanoyl homoserine lactone (OHHL), the most active
autoinducer in the Escherichia coli bioassay. Most of the
natural AHLs 3a–f showed agonistic activity in the whole range
of tested concentrations (1000–10 nM) (Table 1). In correspon-
dence with previous studies this indicates that the 3-oxo moiety
of the fatty acid chain is not an absolute requirement for activity
in this biosensor [32].
As expected, the activity of the natural AHLs 3 decreased with
increasing acyl chain length with N-hexanoyl and N-heptanoyl
homoserine lactone 3a and 3b showing the highest activity.
Introduction of a chlorine atom at the α-position of the acyl
chain lead to a decrease of GFP production as can be seen for
analogues 11a,b (Figure 2).
In general chlorinated lactones 11a–f were the most active
among the α-haloacylated analogues. Nevertheless, this modifi-
cation reduced the activity as compared to the natural AHLs
3a–f with the same N-acyl chain length except for 11e. Bromi-
nated analogues 6a–f showed a further reduced activity when
compared to their corresponding natural and chlorinated
analogues. α-Bromo lactones 6a–b showed a significantly lower
activity (less than half of the activity of their corresponding
natural AHLs 3a,b) whereas 6d–f showed practically no
activity in the whole concentration range (1000–10 nM). Iodi-
nated lactones 8a–f demonstrated the lowest activity, with very
low or no activity in the concentration range of 500 nM to
10 nM. Even at the highest concentration tested (1000 nM),
introduction of iodine had a tremendous effect and reduced the
activity with more than 75% as can be seen for analogues 8a,b
Beilstein J. Org. Chem. 2014, 10, 2539–2549.
2543
Table 1: Quorum sensing-regulated GFP production by Escherichia coli JB523 induced by natural AHLs 3 and α-haloacylated analogues 6, 8 and
11a.
Compound Concentration
R X 1000 nM 750 nM 500 nM 250 nM 100 nM 10 nM
3a C4H9 H 98 ± 4.3 72.9 ± 5.3 58.2 ± 3.3 40 ± 3.6 34.8 ± 2.3 5.7 ± 1.4
11a C4H9 Cl 48.1 ± 4.0 46.9 ± 6.7 42 ± 3.9 37.4 ± 1.5 25.7 ± 2.9 1.2 ± 0.9
6a C4H9 Br 19.6 ± 2.1 21 ± 2.5 14.8 ± 3.4 7.3 ± 4.4 2.6 ± 1.3 0 ± 1.1
8a C4H9 I 26.8 ± 6.0 16.9 ± 5.2 12.5 ± 6.9 7.5 ± 7.8 1.2 ± 2.1 0.1 ± 1.4
3b C5H11 H 74.6 ± 6.1 91.6 ± 2.1 74.5 ± 3.8 81.1 ± 7.4 70.6 ± 6.0 29.1 ± 11.2
11b C5H11 Cl 63 ± 3.3 69 ± 10.0 56.9 ± 3.1 54.2 ± 7.9 27.5 ± 5.2 3.2 ± 10.0
6b C5H11 Br 24.2 ± 0.5 20 ± 2.6 14.4 ± 2.7 10.5 ± 3.7 4.4 ± 3.9 0.2 ± 2.9
8b C5H11 I 4 ± 8.9 2.2 ± 3.3 1.6 ± 3.1 0.8 ± 1.9 0.3 ± 2.5 0.1 ± 1.3
3c C6H13 H 57 ± 9.3 59.8 ± 6.3 45.4 ± 1.5 50.8 ± 7.2 39.1 ± 3.2 12.1 ± 2.9
11c C6H13 Cl 31.4 ± 3.0 28.4 ± 5.3 24 ± 2.6 16.8 ± 3.6 7.7 ± 3.7 0.5 ± 1.4
6c C6H13 Br 30.8 ± 42.4 21.8 ± 20.7 12.1 ± 33.1 13.4 ± 8.4 2.5 ± 29.2 1.4 ± 5.7
8c C6H13 I 21.7 ± 37.3 30.9 ± 2.8 8.5 ± 30.0 7.1 ± 11.3 1 ± 18.0 0.6 ± 5.3
3d C7H15 H 45 ± 5.7 51.5 ± 5.6 42.5 ± 8.3 41.2 ± 4.8 24.2 ± 3.8 1.1 ± 1.2
11d C7H15 Cl 12.4 ± 5.9 9.8 ± 2.1 5.8 ± 3.1 2.9 ± 2.4 1.2 ± 2.9 0 ± 4.8
6d C7H15 Br 2.4 ± 2.2 2.2 ± 20.2 0.6 ± 3.1 0.5 ± 15.1 0 ± 2.9 0 ± 6.7
8d C7H15 I 0.2 ± 1.6 0.2 ± 15.3 0 ± 2.0 0 ± 10.2 0 ± 12.9 0 ± 9.3
3e C8H17 H 61.7 ± 4.9 42 ± 4.4 27 ± 4.2 8.5 ± 3.0 1.9 ± 3.7 0 ± 3.6
11e C8H17 Cl 50 ± 6.5 54.2 ± 5.0 47.9 ± 3.1 30.7 ± 2.4 10.9 ± 3.8 0.5 ± 2.9
6e C8H17 Br 4.4 ± 13.9 2.2 ± 4.7 1.3 ± 3.1 0 ± 1.9 0 ± 2.1 0 ± 2.4
8e C8H17 I 0 ± 8.9 0 ± 6.5 0 ± 12.1 0 ± 1.9 0 ± 3.5 0 ± 2.0
3f C10H21 H 18.1 ± 2.7 7 ± 5.3 2.8 ± 3.4 1.4 ± 7.3 0.4 ± 2.9 0 ± 5.9
11f C10H21 Cl 0.8 ± 2.0 0.5 ± 4.8 1.3 ± 36.9 0.3 ± 2.8 0.1 ± 1.6 0 ± 2.4
6f C10H21 Br 1.3 ± 4.6 0.3 ± 2.5 0.4 ± 2.1 0.1 ± 1.5 3.6 ± 2.8 0 ± 1.9
8f C10H21 I 2.9 ± 4.9 1.4 ± 2.5 0.8 ± 1.5 0.4 ± 2.8 0.3 ± 2.9 0 ± 2.9
aGFP production was determined by measuring specific fluorescence. GFP fluorescence was corrected for cell density of the reporter strain (fluores-
cence/OD600 nm). Phosphate buffered saline was used as control; the specific fluorescence observed for 50 nM of OHHL was set at 100% and the
other values were normalized accordingly. Results are expressed as mean value ± standard deviation of six repetitions.
(Figure 2). Overall, these results demonstrate that the agonistic
activity of the different halogenated analogues (Cl > Br > I)
correlated with the electronegativity and possible n→π* attenu-
ation of the α-halogen (Cl > Br > I). The α-halogenated
analogues 6, 8 and 11 were then screened in an inhibition test
competing with OHHL in the Escherichia coli JB523 bioassay
to evaluate their ability to disrupt QS (Table 2). None of the
α-chloro lactones 11 showed a significant reduction of QS regu-
lated GFP-production in the tested concentration range
(50–0.05 μΜ). Brominated analogues 6 demonstrated a small
decrease in the activity. Among these analogues, compounds 6d
and 6a inhibited QS the most in the concentration of 50 μΜ and
0.5 μΜ, respectively. α-Iodo lactones 8c,d exhibited a 25%
decrease in the 50 μΜ concentration.
It could be expected that, due to attenuation of the n→π* inter-
action and the subsequent effect on the conformation of the
molecules as it was recently suggested, introduction of electron-
withdrawing groups in α-position of the carbonyl group could
lead to higher affinity of these analogues towards the receptor
[18]. However, under the tested conditions the halogenated
analogues 6, 8 and 11 did not demonstrate a significantly higher
QS activity, although most α-chlorinated analogues 11 retained
a significant amount of QS activity. It has been reported that the
trans conformation, in which the dihedral angle between the
carbonyl oxygen and the α-chloro atom is ~180°, is the most
stable conformation of 2-chloroacetamide in solution. In this
conformation the C–Cl bond dipole is aligned in parallel with
the N–H bond dipole, promoting a favorable electrostatic inter-
action [33].
The occurrence of these favorable trans conformations would
result in opposite face orientations of the alkyl chain of the
different diastereoisomers of N-chloroacyl-(S)-homoserine
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Figure 2: Normalized fluorescence values for natural AHLs 3a,b and α-haloacylated analogues 6, 8 and 11 tested in various concentrations. A; com-
parison of AHLs with chain length of 6 carbons. B; comparison of AHLs with chain length of 7 carbons. See Supporting Information File 1 for full
experimental data.
lactones 11. As can be seen from the proposed models
(Chem3D Pro) in which N-(2R)- and N-(2S)-chlorohexanoyl-
(S)-homoserine lactone 11a (Figure 3) are aligned with the opti-
mized structure of N-tribromoacetyl homoserine lactone [18],
for the N-(2R)-chlorohexanoyl-(S)-homoserine lactone 11a the
alkyl group is in a position with more steric interactions
between the alkyl chain and the lacton ring as compared to the
conformation of N-(2S)-chlorohexanoyl-(S)-homoserine lactone
11a. This possible steric hindrance could contribute to attenua-
tion of the n→π* interaction. The influence of these possible
conformational effects, combined with the electron-with-
drawing effect of the halogens, will be subject of future theo-
retical calculations.
Due to the presence of the halogen as an electrophilic moiety, it
could be possible that the reduced activity of the novel halo-
genated analogues 6, 8 and 11 originates from a covalent
binding of the halogenated analogues in the binding site of the
target receptor [15]. The absence of antagonistic activity of
these molecules in this biosensor however indicates that the
reduction in QS activity results from the presence of the larger
electron-withdrawing halogen substituents (covalent radius H:
0.37 Å; Cl: 0.99 Å; Br: 1.14 Å; I: 1.33 Å) which causes changes
in the steric and electronic properties of the N-acyl chain. These
results are in agreement with a previous study where it was
demonstrated that the final cleavage of the acyl chain and not
the halogenation itself leads to the deactivation of β-keto AHLs
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Table 2: Inhibition of QS regulated GFP production in the Escherichia coli JB 523 bioassay by α-haloacylated analogues 6, 8 and 11a.
Compound Concentration
R X 50 µM 25 µM 12.5 µM 5 µM 0.5 µM 0.05 µM 0 µM
11a C4H9 Cl 77.9 ± 51.5 108 ± 2.3 97.6 ± 2.5 95.1 ± 1.8 91.1 ± 1.7 95.4 ± 2.5 100 ± 2.0
6a C4H9 Br 97.9 ± 4.7 101 ± 5.0 90.9 ± 6.9 86.2 ± 7.4 71.6 ± 3.8 84.1 ± 2.0 100 ± 3.5
8a C4H9 I 101 ± 7.1 97.5 ± 2.5 95.4 ± 3.7 91.8 ± 2.0 98.2 ± 1.5 97.7 ± 2.1 100 ± 2.4
11b C5H11 Cl 105 ± 1.2 104 ± 2.3 105 ± 1.9 103 ± 1.9 99.8 ± 2.3 94.6 ± 2 100 ± 2.8
6b C5H11 Br 82.5 ± 6.0 79 ± 2.0 78.9 ± 2.1 82.5 ± 2.9 88.1 ± 4.1 93.8 ± 4.0 100 ± 3.1
8b C5H11 I 73.4 ± 2.9 69.4 ± 15.3 77.7 ± 3.4 83.9 ± 2.6 94.3 ± 3.5 97 ± 2.7 100 ± 2.6
11c C6H13 Cl 98.6 ± 3.0 95.5 ± 2.3 91.4 ± 5.9 85.9 ± 2.6 93.2 ± 3.0 96.4 ± 2.9 100 ± 4.4
6c C6H13 Br 85.2 ± 2.5 77.9 ± 3.0 79.8 ± 4.4 74.9 ± 1.4 91 ± 2.6 97 ± 3.7 100 ± 13.1
8c C6H13 I 75.5 ± 1.7 79.3 ± 1.8 85.1 ± 4.2 88.8 ± 1.6 98.2 ± 2.0 94.1 ± 2.4 100 ± 2.7
11d C7H15 Cl 84.7 ± 2.7 81.5 ± 1.5 81.7 ± 2.3 84.6 ± 3.0 94.2 ± 1.6 96.4 ± 0.9 100 ± 2.0
6d C7H15 Br 68.2 ± 2.0 73.6 ± 3.5 77.7 ± 10.8 88.3 ± 2.0 95.6 ± 3.3 95.3 ± 1.5 100 ± 2.1
8d C7H15 I 75.3 ± 1.5 83.1 ± 5.2 94.2 ± 3.1 93.5 ± 1.3 101 ± 2.2 98.2 ± 3.7 100 ± 2.4
11e C8H17 Cl 84.3 ± 33.8 118 ± 7.4 93.2 ± 3.5 106 ± 5.0 93.9 ± 7.8 105 ± 4.0 100 ± 1.7
6e C8H17 Br 86.9 ± 4.6 94.8 ± 2.3 90.9 ± 8.8 104 ± 2.3 105 ± 3.2 113 ± 9.6 100 ± 3.5
8e C8H17 I 100 ± 6.6 108 ± 7.8 111 ± 2.5 101 ± 4.5 119 ± 14.6 120 ± 12.6 100 ± 16.1
11f C10H21 Cl 86 ± 5.6 93.4 ± 4.4 90.6 ± 3.0 90.5 ± 3.1 90.6 ± 2.2 98.5 ± 4.1 100 ± 1.0
6f C10H21 Br 77.9 ± 5.4 91.4 ± 11.0 81.4 ± 7.5 89.6 ± 3.6 78 ± 5.2 84.9 ± 2.6 100 ± 2.3
8f C10H21 I 90.7 ± 2.0 90.1 ± 2.5 90.2 ± 1.8 93.8 ± 1.6 98.8 ± 1.7 96.9 ± 0.9 100 ± 2.0
aInhibition of quorum sensing-regulated GFP production in the Escherichia coli JB523 bioassay by α-haloacylated analogues 6, 8 and 11 in the pres-
ence of 50 nM of OHHL. GFP production was determined by measuring specific fluorescence. GFP fluorescence was corrected for cell density of the
reporter strain (Fluorescence/OD600 nm). Phosphate buffer saline was used as control; the specific fluorescence observed for 50 nM of OHHL was
set at 100% and the other values were normalized accordingly. Results are expressed as mean value ± standard deviation of six repetitions.
Figure 3: Proposed models (Chem3D Pro) of N-(2R)- (left) and N-(2S)-chlorohexanoyl-(S)-homoserine lactone (right) 11a aligned with the optimized
structure of N-tribromoacetyl homoserine lactone (middle) [18].
[34]. In summary, it can be suggested that some of these
novel halogenated analogues 6, 8 and especially 11 could be
utilized as tools in QS research, e.g., with wild type bacteria
or other reporter strains because of their partially retained
activity and the absence of antagonistic effects presently
demonstrated.
Conclusion
In conclusion, new AHL analogues were designed by introduc-
tion of a halogen atom in α-position of the N-acyl chain and
their bioactivity as QS modulators has been evaluated. α-Halo-
genated AHL analogues exhibited a reduction in activity as
compared to the activity of the corresponding natural analogues
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with the same N-acyl chain in the E. coli JB523 bioassay. These
results do not directly support the recent suggestion that modifi-
cations, i.e., introduction of halogens that weakens the n→π*
interaction should increase the affinity of AHL analogues with
the cognate receptor [18]. However, the activity of the novel
compounds is modulated by the steric and electronic effects
induced by the larger halo substituents. Furthermore, the
absence of antagonistic activity of the novel analogues and the
retained QS activity of most of the chlorinated analogues in
comparison with the natural ligands encourages the utilization
of these functionalized compounds as possible tools for further
exploration of QS structure–activity studies.
Experimental
Chemistry
Synthesis of homoserine lactone hydrobromide 1
As already described in [34] a mixture of (S)-methionine
(15.2 g; 0.10 mol) and bromoacetic acid (1.1 equiv, 15.4 g,
0.11 mol) in 150 mL of a H2O–iPrOH–AcOH mixture (5:5:2
v:v:v) was stirred under reflux overnight. The solvent was then
removed under reduced pressure. Subsequently, the orange
sticky oil was partly dissolved in 50 mL of a 4:1 mixture (v:v)
of iPrOH–HBr (30% in AcOH). The title compound was
collected by filtration and the purification procedure was
repeated starting by evaporation of the orange filtrate to
dryness. Compound 1 was collected as a beige powder, mp
227–229 °C (mp 226–228 °C [25]). All other physical and
analytical data were in agreement with those previously
reported.
Synthesis of natural AHLs 3 using
Schotten–Baumann conditions
The appropriate acid chloride 2 (4 mmol) was added dropwise
at room temperature to a vigorously stirred mixture of (S)-
homoserine lactone hydrobromide (1, 1.3 equiv, 0.95 g,
5.2 mmol) and Na2CO3 (2.6 equiv, 0.55 g, 10.4 mmol) in water
(5 mL per mmol acid chloride) and CH2Cl2 (5 mL per mmol
acid chloride). The mixture was stirred vigorously at room
temperature for 2 h. CH2Cl2 was added, the aqueous and
organic phases were separated and the aqueous phase was
extracted with CH2Cl2 (2 × 20 mL). The combined organic
extracts were washed with saturated aqueous NaHCO3
(2 × 40 mL), dried (MgSO4), filtered and the solvent removed
under reduced pressure to yield the desired product 3. The crude
product was purified via column chromatography on silica gel
(EtOAc/petroleum ether 4:1).
Synthesis of α-brominated fatty acids 5b–f
To a flask equipped with a sodium hydroxide trap the corres-
ponding fatty acid 4 (0.065 mol) and thionyl chloride (5 equiv,
40 mL, 0.325 mol) were added. The reaction mixture was
stirred at 50 °C in a water bath. Then, liquid bromine (3 equiv,
5 mL, 0.195 mol) was added dropwise and the reaction mixture
was stirred under reflux for 6 h and then at room temperature
overnight. The excess of thionyl chloride was then removed by
distillation. To a beaker containing distilled water in an ice bath,
the dark red residue was slowly added and manually stirred.
Afterwards, the solution was heated and subsequently cooled,
resulting in the precipitation of a pale yellow solid for the
longer chain fatty acids which was decanted, washed with
distilled water, and once again submitted to the crystallization
procedure.
Synthesis of α-iodinated fatty acids 7a–d
The appropriate α-bromo fatty acid 5 (3 mmol) and sodium
iodide (2 equiv, 0.90 g, 6 mmol) were dissolved in 10 mL of
2-butanone. The reaction mixture was stirred under reflux for
7 h. Subsequently the solvent was removed under reduced pres-
sure and the brown residue was dissolved in distilled water and
subsequently decolorized by dropwise addition of 10% aq
NaHSO3. The solution was then acidified with 5% aq H2SO4,
yielding a black oil which was separated from the aqueous
phase by decantation. Distilled water was then added and the
suspension was heated to boiling with the dropwise addition of
10% aq NaHSO3 until complete clearing of the oil. The aqueous
phase was removed and the yellow oil was dissolved in a satu-
rated aq NaHCO3 solution, the medium was acidified with 5%
aq H2SO4 and heated. The dense yellow oil was extracted with
ethyl acetate, dried over anhydrous magnesium sulfate, filtered
and evaporated under reduced pressure.
Synthesis of α-iodinated fatty acids 7e,f
As described in [28] fatty acid 4e or 4f (1.56 mmol), iodine
(0.5 equiv, 0.20 g, 0.78 mmol) and chlorosulfonic acid (1 equiv,
0.1 mL, 1.56 mmol) were dissolved in 1.6 mL of dry 1,2-
dichloroethane. The reaction mixture was heated at 80 °C for
5 h, after which it was diluted with 3 mL 1,2-dichloroethane
and washed successively with water (2 × 5 mL) and an aqueous
0.1 M Na2S2O3 solution until the color changed from pink to
white. The organic phase was dried with MgSO4, filtered and
evaporated in vacuo.
Synthesis of α-bromo-acylated homoserine lactones
6a–f and α-iodo acylated homoserine lactones 8a–f
As described in [34] to a stirred solution of (S)-homoserine
lactone hydrobromide (1, 0.36 g, 2 mmol) in 5 mL of water,
triethylamine (1 equiv, 0.28 mL, 2 mmol) was added followed
by the addition of the appropriate brominated or iodinated fatty
acid 5 or 7 (1.5 equiv, 3 mmol) and 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (1.5 equiv, 0.58 g, 3 mmol). The
mixture was stirred overnight at room temperature. The aqueous
phase was extracted two times with ethyl acetate and the
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organic phase was washed with saturated aq NaHCO3 solution
and brine. Drying with MgSO4, filtration and evaporation of the
solvent gave the corresponding acylated homoserine lactones 6
and 8. The crude product was purified via column chromatog-
raphy on silica gel (EtOAc/petroleum ether 4:1).
Synthesis of α-chloro acylated homoserine lactones
11a–f
In a flask containing the appropriate acid chloride 2 (5 mmol)
which was kept under a nitrogen atmosphere at 0 °C, P(OMe)3
(1.16 equiv, 1.45 mL, 5.8 mmol) was added. The mixture was
stirred for 4 h at room temperature. Then the excess of P(OMe)3
and MeCl were evaporated under reduced pressure. The flask
was covered with aluminium foil and SO2Cl2 (1.3 equiv,
0.52 mL, 6.5 mmol) was added via a syringe at 0 °C. After stir-
ring for 14 h at room temperature, the reaction was quenched by
adding 5 mL of dry CH2Cl2 and bubbling nitrogen through the
solution to remove excess of SO2Cl2 and HCl. The chlorinated
acylphosphonates 10 were added at 0 °C to a bulb containing
(S)-homoserine lactone 1 (1.3 equiv, 1.18 g, 6.5 mmol) and
Et3N (2.6 equiv, 1.8 mL, 13 mmol) in 10 mL of dry CH2Cl2.
This reaction mixture was stirred for 4 h at room temperature
under nitrogen. Then the mixture was poured into 20 mL
0.1 M aq HCl and extracted with 20 mL of CH2Cl2. The
organic phase was dried with MgSO4, filtered to remove the
MgSO4 and the solvent was removed under reduced pressure.
The crude product was purified by column chromatography on
silica gel (EtOAc/petroleum ether 4:1) to give the desired prod-
uct.
Characterization of novel compounds
Representative characterization data for novel analogues. Char-
acterization of all compounds can be found in the Supporting
Information File 2 of this article.
2-Bromo-N-[(3S)-tetrahydro-2-oxo-3-furanyl]hexan-
amide) (6a)
1H NMR (300 MHz, CDCl3) δ 0.92 (t, J = 7.0 Hz, 3H,
CH3isomer 1 and 2), 1.30–1.53 (m, 4H, (CH2)2CH3isomer 1 and 2),
1.94–2.07 (m, 1H, CHH'CHBrisomer 1 and 2), 2.08–2.16 (m, 1H,
C H H ' C H B r i s o m e r  1  a n d  2 ) ,  2 . 1 6 – 2 . 3 0  ( m ,  1 H ,
O C H 2 C H H ' i s o m e r  1  a n d  2 ) ,  2 . 7 9 – 2 . 9 0  ( m ,  1 H ,
OCH2CHH'isomer 1 and 2), 4.22–4.36 (m, 2H, CHBrisomer 1 and 2
and OCHH ' i somer  1  and 2),  4.50 (t,  J  = 9.1 Hz, 1H,
OCHH'isomer 1 and 2), 4.52–4.61 (m, 1H, CHNisomer 1 and 2), 7.01
(d, J = 5.5 Hz, 1H, NH,isomer 1 and 2); 13C NMR (75 MHz,
CDCl3) δ 13.9 (CH3isomer 1 and 2), 22.0 (CH2CH3isomer 1 and 2),
29.35 (CH2CH2CHBrisomer 1), 29.39 (CH2CH2CHBrisomer 2),
29.9 (CH2CHNisomer 1 and 2), 35.36 (CH2CHBrisomer 1), 35.41
(CH2CHBr i somer  2) ,  49.8 (CHN i somer  1  and  2) ,  50.3
(CHBrisomer 1), 50.4 (CHBrisomer 2), 66.17 (CH2Oisomer 1),
66.20 (CH2O i somer  2),  169.8 (NC=O i somer  1),  169.9
(NC=Oisomer 2), 174.9 (OC=Oisomer 1), 175.0 (OC=Oisomer 2);
MS (ESI) m/z (%): 278/280 (M + H+, 100); HRMS calcd for
C10H16BrNO3H+, 278.0386; found, 278.0378; IR (cm−1) νmax:
1008, 1178 (C-O), 1554 (HN-C=O), 1655 (HN-C=O), 1769
(C=Olactone), 2860 (CH), 2924 (CH), 2957 (CH), 3298 (NH);
chromatography: EtOAc/PE 4:1 Rf 0.48; melting point: 148 °C;
white powder; yield: 54%.
2-Iodo-N-[(3S)-tetrahydro-2-oxo-3-furanyl]hexan-
amide) (8a)
1H NMR (300 MHz, CDCl3) δ 0.91 (t, J = 7.2 Hz, 3H,
CH3, isomer 1 and 2), 1.21–1.50 (m, 4H, (CH2)2CH3, isomer 1 and 2),
1.99 (q, J =7.2 Hz, 2H, CH2CHIisomer 1 and 2), 2.11–2.29 (m,
1H,  OCH2CHH' i s o m e r  1  a n d  2 ) ,  2 .82–2.94 (m,  1H,
O C H 2 C H H ' i s o m e r  1  a n d  2 ) ,  4 . 2 6 – 4 . 3 6  ( m ,  1 H ,
OCHH'isomer 1 and 2), 4.30 (t, J = 7.2 Hz, 1H, CHIisomer 1 and 2),
4.46–4.53 (m, 0.5H, CHNisomer 1), 4.51 (t, J = 8.8 Hz, 1H,
OCHH'isomer 1 and 2), 4.60 (ddd, J = 11.8 Hz, 8.5 Hz, 6.1 Hz,
0.5H, CHNisomer 2), 6.43 (d, J = 6.1 Hz, 0.5H, NHisomer 1), 6.52
(d, J = 6.1 Hz, 0.5H, NHisomer 2); 13C NMR (75 MHz, CDCl3)
δ  1 3 . 9  ( C H 3 ,  i s o m e r  1  a n d  2 ) ,  2 2 . 0  a n d  3 1 . 6
((CH2)2CH3, isomer 1 and 2), 24.9 (CHIisomer 1 and 2), 29.6
(CH2CHN i s o m e r  1 ) ,  29 .7  (CH2CHN i s o m e r  2 ) ,  36 .2
(CH2CHIisomer 1), 36.3 (CH2CHIisomer 2), 49.6 (CHNisomer 1),
49.8 (CHN isomer 2), 66.3 (CH2O isomer 1 and 2), 171.4
(NC=Oisomer 1 ), 171.5 (NC=Oisomer 2), 175.3 (OC=Oisomer 1),
175.4 (OC=Oisomer 2); MS (ESI) m/z (%): 326 (M + H+, 100);
HRMS calcd for C10H16INO3H+, 326.0253; found, 326.0244;
IR (cm−1) νmax: 1016, 1176 (C-O), 1546 (HN-C=O), 1642 (HN-
C=O), 1770 (C=Olactone), 2858 (CH), 2929 (CH), 2956 (CH),
3296 (NH); chromatography: EtOAc/PE 4:1 Rf 0.62; melting
point: 152 °C; yellowish powder; yield: 49%.
2-Chloro-N-[(3S)-tetrahydro-2-oxo-3-furanyl]hexan-
amide) (11a)
1H NMR (300 MHz, CDCl3) δ 0.92 (t, J = 7.2 Hz, 3H,
CH3, isomer 1 and 2), 1.26–1.55 (m, 4H, (CH2)2CH3isomer 1 and 2),
1.87–2.01 (m, 1H, CHH'CHClisomer 1 and 2), 2.05–2.18 (m, 1H,
CHH'CHClisomer 1 and 2), 2.26 (dddd, J = 11.8 Hz, 11.8 Hz, 11.7
Hz, 8.8 Hz, 1H, OCH2CHH'isomer 1 and 2), 2.74–2.84 (m, 1H,
OCH2CHH’isomer 1 and 2), 4.27–4.40 (m, 2H, CHClisomer 1 and 2
and OCHH ' i somer  1  and 2),  4.50 (t,  J =  8.8 Hz, 1H,
OCHH'isomer 1 and 2), 4.55–4.64 (m, 1H, CHNisomer 1 and 2), 7.22
(d, J = 6.1 Hz, 0.5H, NHisomer 1), 7.25 (d, J = 6.1 Hz, 0.5H,
NH i s o m e r  2 ) ;  1 3C NMR (75 MHz,  CDCl3 )  δ  13 .9
(CH3, isomer 1 and 2), 22.0 (CH2CH3, isomer 1 and 2), 27.9
(CH2CH2CHClisomer 1), 28.0 (CH2CH2CHClisomer 2), 29.7
(CH2CHNisomer 1 and 2), 35.2 (CH2CHClisomer 1 and 2), 49.4
(CHNisomer 1), 49.5 (CHNisomer 2), 60.47 (CHClisomer 1), 60.50
(CHClisomer 2), 66.07 (CH2Oisomer 1), 66.12 (CH2Oisomer 2),
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169.96 (NC=Oisomer 1), 170.00 (NC=Oisomer 2), 174.8
(OC=Oisomer 1), 174.9 (OC=Oisomer 2); MS (ESI) m/z (%): 234/
236 (M + H+, 100); HRMS calcd for C10H16ClNO3H+,
234.0897; found, 234.0889; IR (cm−1) νmax: 1014, 1172 (C-O),
1553 (HN-C=O), 1656 (HN-C=O), 1771 (C=Olactone), 2860
(CH), 2930 (CH), 2958 (CH), 3298 (NH); chromatography:
EtOAc/PE 4:1 Rf 0.48; melting point: 144 °C; white powder;
yield: 42%.
Biological evaluation
Escherichia coli JB523 green fluorescent protein
(GFP) microplate assay
Strain JB523 was grown overnight at 28 °C in Luria–Bertani
(LB) medium supplemented with 20 mg/L tetracycline until
optical density (OD) reached approximately 1 at 550 nm. The
bacteria were then diluted to an OD600 of 0.1. Then 100 μL of
the diluted culture was mixed with 100 μL of the appropriate
concentration of the tested compound. Phosphate buffered
saline (PBS) was used to prepare the stock solutions for all
concentrations. PBS was used as a negative control for acti-
vation tests. For the inhibition tests the procedure was the same
with the exception of the addition of 50 nM of OHHL to the
culture medium. The plate was incubated at 28 °C for 24 h.
QS-regulated GFP production was then assessed by fluores-
cence measurements (excitation at 475 nm and emission at
515 nm) using a PerkinElmer VICTOR X multilabel plate
reader. The fluorescence was normalised for cell density of the
reporter strain.
Supporting Information
Supporting Information File 1
Graphical representation of QS activity of natural and
α-haloacylated analogues.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-10-265-S1.pdf]
Supporting Information File 2
1H and 13C NMR data and spectra, IR, HRMS, optical
rotation and melting point data, chromatographic separation
and yields of synthesized compounds.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-10-265-S2.pdf]
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